BRPI0408113A - methods for treating or preventing a central nervous system disorder, for controlling a central nervous system disorder and for reducing or preventing an adverse effect associated with the administration of a secondary active ingredient in a patient suffering from a central nervous system disorder, and pharmaceutical composition - Google Patents

methods for treating or preventing a central nervous system disorder, for controlling a central nervous system disorder and for reducing or preventing an adverse effect associated with the administration of a secondary active ingredient in a patient suffering from a central nervous system disorder, and pharmaceutical composition

Info

Publication number
BRPI0408113A
BRPI0408113A BRPI0408113-7A BRPI0408113A BRPI0408113A BR PI0408113 A BRPI0408113 A BR PI0408113A BR PI0408113 A BRPI0408113 A BR PI0408113A BR PI0408113 A BRPI0408113 A BR PI0408113A
Authority
BR
Brazil
Prior art keywords
central nervous
nervous system
system disorder
preventing
methods
Prior art date
Application number
BRPI0408113-7A
Other languages
Portuguese (pt)
Inventor
Peter H Schafer
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of BRPI0408113A publication Critical patent/BRPI0408113A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODOS PARA TRATAR OU PREVENIR UM DISTúRBIO DO SISTEMA NERVOSO CENTRAL, PARA CONTROLAR UM DISTúRBIO DO SISTEMA NERVOSO CENTRAL E PARA REDUZIR OU EVITAR UM EFEITO ADVERSO ASSOCIADO COM A ADMINISTRAçãO DE UM INGREDIENTE ATIVO SECUNDáRIO EM UM PACIENTE QUE SOFRE DE UM DISTúRBIO DO SISTEMA NERVOSO CENTRAL, E, COMPOSIçãO FARMACêUTICA". Métodos de tratar, prevenir e/ou controlar distúrbios do sistema nervoso central, tais como mal de Parkinson, mal de Alzheimer, deterioração cognitiva branda, doença de Huntington, Esclerose Lateral Amiotrófica, depressão e memória de longa duração defeituosa e síndromes relacionadas são divulgados. Os métodos específicos abrangem a administração de um medicamento inibidor de citocina seletivo ou um sal, solvato, hidrato, estereoisómero, clatrato ou pró-medicamento deste farmaceuticamente aceitáveis, sozinhos ou em combinação com um segundo ingrediente ativo. Composições farmacêuticas, formas de dosagem unitária única e kits adequados para o uso nos métodos da invenção também são divulgados."METHODS FOR TREATING OR PREVENTING CENTRAL NERVOUS SYSTEM DISORDER, TO CONTROL CENTRAL NERVOUS SYSTEM DISORDER AND TO REDUCING OR AVOIDING AN ADVERSE EFFECT ASSOCIATED WITH A CENTRAL NERVOUS INGREDIENT SYSTEM , AND PHARMACEUTICAL COMPOSITION ". Methods of treating, preventing and / or controlling central nervous system disorders such as Parkinson's disease, Alzheimer's disease, mild cognitive impairment, Huntington's disease, Amyotrophic Lateral Sclerosis, depression and defective long-term memory, and related syndromes. Specific methods include administering a selective cytokine inhibitor medicament or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate or prodrug thereof alone or in combination with a second active ingredient. Pharmaceutical compositions, single unit dosage forms and kits suitable for use in the methods of the invention are also disclosed.

BRPI0408113-7A 2003-03-06 2004-03-05 methods for treating or preventing a central nervous system disorder, for controlling a central nervous system disorder and for reducing or preventing an adverse effect associated with the administration of a secondary active ingredient in a patient suffering from a central nervous system disorder, and pharmaceutical composition BRPI0408113A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45237403P 2003-03-06 2003-03-06
PCT/US2004/006782 WO2004080393A2 (en) 2003-03-06 2004-03-05 Selective cytokine inhibitory drugs for treating disorders of the central nervous system

Publications (1)

Publication Number Publication Date
BRPI0408113A true BRPI0408113A (en) 2006-03-01

Family

ID=32990646

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408113-7A BRPI0408113A (en) 2003-03-06 2004-03-05 methods for treating or preventing a central nervous system disorder, for controlling a central nervous system disorder and for reducing or preventing an adverse effect associated with the administration of a secondary active ingredient in a patient suffering from a central nervous system disorder, and pharmaceutical composition

Country Status (12)

Country Link
EP (1) EP1605935A4 (en)
JP (1) JP2006519875A (en)
KR (1) KR100831545B1 (en)
CN (1) CN1780616B (en)
AU (1) AU2004220607B2 (en)
BR (1) BRPI0408113A (en)
CA (1) CA2517845A1 (en)
IL (1) IL170710A0 (en)
MX (1) MXPA05009435A (en)
NZ (1) NZ542408A (en)
WO (1) WO2004080393A2 (en)
ZA (1) ZA200507322B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
EA202092673A3 (en) 2010-02-09 2021-05-31 Дзе Джонс Хопкинс Юниверсити METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
JP2017141222A (en) * 2016-02-09 2017-08-17 国立大学法人帯広畜産大学 Therapeutic agent for cognitive impairment associated with Parkinson's disease and screening method therefor
LT3697399T (en) * 2017-10-18 2026-01-12 Intrabio Ltd Therapeutic agents for use in the treatment of restless leg syndrome
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
WO2022098106A1 (en) * 2020-11-04 2022-05-12 주식회사 오에이티씨 Composition for preventing or treating neuroinflammatory diseases, comprising chlorpromazine
CN119280228B (en) * 2024-11-06 2025-09-19 桂林医学院附属医院 Medicine with neuroprotection effect for parkinsonism and application thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
AR003951A1 (en) * 1995-05-26 1998-09-30 Pfizer SYNERGIC PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF PARKINSON'S DISEASE AND COMPOSITIONS TO PREPARE IT.
US5728845A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
JP3568749B2 (en) * 1996-12-17 2004-09-22 株式会社デンソー Dry etching method for semiconductor
CA2295295A1 (en) * 1997-07-31 1999-02-11 Celgene Corporation Substituted alkanohydroxamic acids and method of reducing tnf.alpha. levels
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US6471961B1 (en) * 1999-02-24 2002-10-29 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US6623736B2 (en) * 2000-05-02 2003-09-23 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
WO2003080048A1 (en) * 2002-03-20 2003-10-02 Celgene Corporation (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
KR20050000400A (en) * 2002-04-12 2005-01-03 셀진 코포레이션 Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system

Also Published As

Publication number Publication date
CA2517845A1 (en) 2004-09-23
KR100831545B1 (en) 2008-05-21
NZ542408A (en) 2009-03-31
WO2004080393A2 (en) 2004-09-23
CN1780616A (en) 2006-05-31
KR20050109971A (en) 2005-11-22
CN1780616B (en) 2010-05-12
WO2004080393A3 (en) 2004-12-02
AU2004220607B2 (en) 2009-06-11
ZA200507322B (en) 2007-03-28
MXPA05009435A (en) 2005-11-23
AU2004220607A1 (en) 2004-09-23
EP1605935A2 (en) 2005-12-21
EP1605935A4 (en) 2009-05-20
IL170710A0 (en) 2011-08-01
JP2006519875A (en) 2006-08-31

Similar Documents

Publication Publication Date Title
BRPI0418270A (en) methods of treatment and control, treatment or prevention, control of a central nervous system disorder, and to reduce or prevent an adverse effect, and, pharmaceutical composition
BRPI0416260A (en) method for treating, preventing or controlling an asbestos-related disease or disorder and pharmaceutical composition
BRPI0410721A (en) foamable pharmaceutical compositions and methods for treating a disorder
BRPI0415649A (en) method for treating, preventing, modifying or administering pain and pharmaceutical composition
BRPI0509400A (en) methods for treating or preventing dysfunctional sleep, controlling dysfunctional sleep and improving time to sleep, duration of sleep or quality of sleep, or enhancing ability to get up feeling refreshed after a night's sleep, pharmaceutical composition , and, kit suitable for use in the treatment, prevention or control of dysfunctional sleep
BRPI0517481A (en) method for treating, controlling or preventing a protozoan parasitic disease or disorder, and, pharmaceutical composition
BR0316050A (en) Methods of treating, controlling or preventing specific cancer and disease associated with unwanted angiogenesis and reducing or preventing an adverse effect associated with the administration of a second active ingredient and with radiation therapy, hormone therapy, biological therapy, or immunotherapy in a patient. suffering from a specific cancer, pharmaceutical composition and kit
BRPI0518282A2 (en) use of a therapeutically or prophylactically effective amount of an immunomodulatory compound
BRPI0415971A (en) method for treating, preventing or controlling macular degeneration, and pharmaceutical composition
BRPI0410306A (en) methods for treating, controlling or preventing a specific cancer, treating, controlling or preventing a disease associated with unwanted angiogenesis, and for reducing or preventing an adverse effect, pharmaceutical composition, and kit.
AR063201A1 (en) PHARMACEUTICAL COMPOSITIONS OF ROPINIROL AND METHODS OF USE OF THE SAME
MX9200992A (en) PHARMACEUTICAL COMPOSITION THAT HAS AS ACTIVE INGREDIENT 3- [2- (DIMETHYLAMINE) ETHYL] -N-METHYL-1H-INDOL-5-METHANOSULFONAMIDE AND PROCEDURE FOR ITS PREPARATION.
DE60228857D1 (en) AMINO PHTALAZINONE DERIVATIVES, USE AS KINASE INHIBITORS, PREPARATION AND PHARMACEUTICAL COMPOSITION
BR0012082A (en) Pharmaceutical formulation for administration comprising morphine and its use
MXPA04000920A (en) Aminoisoxazole derivatives active as kinase inhibitors.
BRPI0416275A (en) methods of treating, controlling or preventing specific cancer and a disease associated with unwanted angiogenesis
BR112014004741A2 (en) at least one chemical entity; pharmaceutical composition; use of a therapeutically effective amount of at least one chemical entity; packaged pharmaceutical composition
BR0316057A (en) Methods of treating, controlling or preventing specific cancer and a disease associated with unwanted angiogenesis and of reducing or preventing an adverse effect associated with the administration of a second active ingredient and with radiation therapy, hormone therapy, biological therapy or immunotherapy in a patient suffering from a specific cancer, pharmaceutical composition and kit
MXPA05009719A (en) Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
BRPI0408113A (en) methods for treating or preventing a central nervous system disorder, for controlling a central nervous system disorder and for reducing or preventing an adverse effect associated with the administration of a secondary active ingredient in a patient suffering from a central nervous system disorder, and pharmaceutical composition
BR9914419A (en) Perception improvement therapy
BRPI0912112B8 (en) pharmaceutical composition comprising compound having a2a adenosine receptor antagonistic activity useful in suppressing analgesic tolerance
BRPI0409434A (en) nasal pharmaceutical formulations and methods for using them
BR0315593A (en) Method of treating, preventing, modifying or controlling pain and pharmaceutical composition
BRPI0519030A2 (en) methods of treating, preventing, or controlling inflammation of the airways and of a disease or disorder of the airways or lungs, and pharmaceutical composition

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/4035; A61P 25/00, 25/16, 25/28

Ipc: A61K 31/4035 (2011.01), A61P 25/00 (2011.01), A61P

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.